SPY756.10 QQQ684.00 BTC/USD73,421.24−0.69%DIA524.23 GLD365.88 TLT80.87

Cormedix Inc

CRMDNASDAQ

Trade with Public

$5.38

0.07831.48%

Last update: Nov 11, 6:57 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Earnings: Q3 2026 earnings announcement before the market open today

Conference Call: Conference call in progress

Click to view the webcast

M&A: Heron Therapeutics (HRTX) announced it will sell assets to Cormedix (CRMD) on Monday, November 9, 2026

Earnings: Q3 2026 earnings announcement before the market open today

Conference Call: Conference call in progress

Click to view the webcast

M&A: Heron Therapeutics (HRTX) announced it will sell assets to Cormedix (CRMD) on Monday, November 9, 2026

Cormedix (CRMD) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Cormedix (CRMD) stock.

Analyst Consensus — 10 Analysts

2S.Buy

8Buy

# Analysts10

Latest Upgrades and Downgrades for Cormedix Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	RBC Capital	Leonid Timashev	PT Raise	Outperform	$14→$15
—	Needham	Serge Belanger	PT Raise	Buy	$12→$14
—	Needham	Serge Belanger	PT Cut	Buy	$15→$12
—	Needham	Serge Belanger	Maintained	Buy	$15
—	Oppenheimer	Les Sulewski	Initiate	Outperform	$15
—	RBC Capital	Leonid Timashev	PT Raise	Outperform	$13→$14
—	RBC Capital	Leonid Timashev	PT Cut	Outperform	$14→$13
—	RBC Capital	Leonid Timashev	PT Raise	Outperform	$13→$14
—	Citizens	Jason N. Butler	Maintained	Market Outperform	$19
—	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$13→$14
—	Needham	Serge Belanger	PT Raise	Buy	$14→$15
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
—	Needham	Serge Belanger	PT Cut	Buy	$15→$14
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
—	HC Wainwright & Co.	Brandon Folkes	PT Cut	Buy	$18→$13
—	RBC Capital	Leonid Timashev	PT Cut	Outperform	$22→$13
—	Needham	Serge Belanger	PT Cut	Buy	$16→$15
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
—	D. Boral Capital	Jason Kolbert	Maintained	Buy	$14
—	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$17→$18

Cormedix Inc

Cormedix (CRMD) Stock Price Target 2026

Latest Upgrades and Downgrades for Cormedix Stock

Cormedix (CRMD) Stock Price Target 2026

Latest Upgrades and Downgrades for Cormedix Stock

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15

PRO
Needham Maintains Buy on Cormedix, Raises Price Target to $14

PRO
Needham Maintains Buy on Cormedix, Lowers Price Target to $12

PRO
Needham Reiterates Buy on Cormedix, Maintains $15 Price Target

PRO
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

People Also Watch

People Also Watch

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15

PRO
Needham Maintains Buy on Cormedix, Raises Price Target to $14

PRO
Needham Maintains Buy on Cormedix, Lowers Price Target to $12

PRO
Needham Reiterates Buy on Cormedix, Maintains $15 Price Target

PRO
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

Cormedix Inc

Cormedix (CRMD) Stock Price Target 2026

Latest Upgrades and Downgrades for Cormedix Stock

Cormedix (CRMD) Stock Price Target 2026

Latest Upgrades and Downgrades for Cormedix Stock

Analyst Ratings News

PRORBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15

PRONeedham Maintains Buy on Cormedix, Raises Price Target to $14

PRONeedham Maintains Buy on Cormedix, Lowers Price Target to $12

PRONeedham Reiterates Buy on Cormedix, Maintains $15 Price Target

PROOppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRORBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

People Also Watch

People Also Watch

Analyst Ratings News

PRORBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15

PRONeedham Maintains Buy on Cormedix, Raises Price Target to $14

PRONeedham Maintains Buy on Cormedix, Lowers Price Target to $12

PRONeedham Reiterates Buy on Cormedix, Maintains $15 Price Target

PROOppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRORBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15

PRO
Needham Maintains Buy on Cormedix, Raises Price Target to $14

PRO
Needham Maintains Buy on Cormedix, Lowers Price Target to $12

PRO
Needham Reiterates Buy on Cormedix, Maintains $15 Price Target

PRO
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15

PRO
Needham Maintains Buy on Cormedix, Raises Price Target to $14

PRO
Needham Maintains Buy on Cormedix, Lowers Price Target to $12

PRO
Needham Reiterates Buy on Cormedix, Maintains $15 Price Target

PRO
Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

PRO
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $14